UroGen Pharma (URGN) Net Income towards Common Stockholders (2017 - 2026)
UroGen Pharma's (URGN) quarterly Net Income towards Common Stockholders came in at -$23.6 million in Q1 2026, up 46.23% YoY from -$16.1 million in Q1 2025, and down 361.93% on a QoQ basis from $9.0 million in Q4 2025.
UroGen Pharma (URGN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$23.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 46.23% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$97.9 million (up 8.6% YoY) and the FY2025 annual result came in at -$118.1 million, down 23.68% from the prior year.
- Net Income towards Common Stockholders fell to -$23.6 million in Q1 2026, from $9.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $9.0 million in Q4 2025 to a low of -$49.9 million in Q2 2025.
- A 5-year average of -$23.3 million and a median of -$25.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 1284.97% — and 2025, when it soared 246.34%.
- Tracing URGN's Net Income towards Common Stockholders over 5 years: stood at -$2.3 million in 2022, then soared by 122.89% to $519000.0 in 2023, then plunged by 1284.97% to -$6.1 million in 2024, then soared by 246.34% to $9.0 million in 2025, then slumped by 361.93% to -$23.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$23.6 million (Q1 2026), $9.0 million (Q4 2025), and -$33.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -14.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.35 Mn |
| Mar 31, 2026 | -23.57 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | -33.35 Mn |
| Jun 30, 2025 | -49.94 Mn |
| Mar 31, 2025 | -43.84 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -23.67 Mn |
| Jun 30, 2024 | -33.40 Mn |
| Mar 31, 2024 | -32.29 Mn |
| Dec 31, 2023 | 519,000.00 |
| Sep 30, 2023 | -21.88 Mn |
| Jun 30, 2023 | -24.14 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -2.27 Mn |
| Sep 30, 2022 | -25.83 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -28.39 Mn |
| Dec 31, 2021 | -1.85 Mn |
| Sep 30, 2021 | -30.21 Mn |